Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

MASS

908 Devices Inc

Apr 24 • 04:00PM ET

5.62

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Medical Devices • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: ARKG VTI VGT IWM VXF IWN SCHA VTWO IWC DFAT

Index	RUT	P/E	-	EPS (ttm)	-1.13	Insider Own	27.56%	Shs Outstand	32.52M	Perf Week	0.54%
Market Cap	184.95M	Forward P/E	-	EPS next Y	-1.13	Insider Trans	-0.71%	Shs Float	23.84M	Perf Month	-14.20%
Income	-36.40M	PEG	-	EPS next Q	-0.36	Inst Own	63.54%	Short Float	5.16%	Perf Quarter	-27.58%
Sales	50.23M	P/S	3.68	EPS this Y	-10.80%	Inst Trans	3.50%	Short Ratio	7.46	Perf Half Y	1.63%
Book/sh	5.09	P/B	1.10	EPS next Y	9.74%	ROA	-16.34%	Short Interest	1.23M	Perf Year	-25.96%
Cash/sh	4.43	P/C	1.27	EPS next 5Y	-	ROE	-20.44%	52W Range	4.85 - 12.51	Perf YTD	-49.91%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-31.19%	ROI	-21.49%	52W High	-55.08%	Beta	1.01
Dividend TTM	-	Quick Ratio	7.04	Sales past 5Y	21.26%	Gross Margin	46.52%	52W Low	15.88%	ATR (14)	0.41
Dividend Ex-Date	-	Current Ratio	7.71	EPS Y/Y TTM	-6.07%	Oper. Margin	-84.42%	RSI (14)	35.48	Volatility	6.06% 6.53%
Employees	230	Debt/Eq	0.04	Sales Y/Y TTM	7.21%	Profit Margin	-72.47%	Recom	1.00	Target Price	15.33
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	25.75%	Payout	-	Rel Volume	0.00	Prev Close	5.62
Sales Surprise	1.38%	EPS Surprise	12.88%	Sales Q/Q	23.26%	Earnings	Mar 05 BMO	Avg Volume	164.88K	Price	5.62
SMA20	-10.12%	SMA50	-16.35%	SMA200	-19.40%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-07-23	Initiated	Stephens	Overweight	$14
Oct-15-21	Resumed	Cowen	Outperform
Jan-12-21	Initiated	William Blair	Outperform
Jan-12-21	Initiated	SVB Leerink	Outperform	$70
Jan-12-21	Initiated	Stifel	Buy	$65
Jan-12-21	Initiated	Cowen	Outperform

Apr-23-24 07:00AM	908 Devices to Report First Quarter 2024 Financial Results on April 30, 2024 (Business Wire)
Mar-12-24 07:00AM	908 Devices Trace Chemical Identification Technology Adopted by European Agencies (Business Wire) +5.41%
Mar-07-24 12:02PM	908 Devices Inc. (NASDAQ:MASS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-05-24 07:33AM	908 Devices Inc (MASS) Reports Growth Amidst Industry Headwinds (GuruFocus.com)
07:00AM	908 Devices Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Revenue Outlook (Business Wire)
07:00AM	Loading…
Feb-29-24 07:00AM	908 Devices and Cellares Collaborate to Integrate In-line Monitoring of Bioprocess Parameters into the Cell Shuttle, Cellares Fully Integrated Cell Therapy Manufacturing Platform (Business Wire)
Feb-22-24 07:00AM	908 Devices to Participate in Upcoming Investor Conferences (Business Wire)
Feb-20-24 07:00AM	908 Devices to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 (Business Wire)
Feb-02-24 11:01PM	908 Devices Inc CFO Griffith Joseph H. IV Sells 15,409 Shares (GuruFocus.com)
Dec-28-23 12:00PM	908 Devices Inc. (MASS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +22.99%
Dec-27-23 10:30AM	2 Cathie Wood Stocks That Could Soar in 2024, According to Wall Street (Motley Fool)
Dec-22-23 01:01PM	Chief Product Officer Christopher Brown Sells 20,000 Shares of 908 Devices Inc (GuruFocus.com)
Dec-19-23 09:55AM	How Much Upside is Left in 908 Devices Inc. (MASS)? Wall Street Analysts Think 100.39% (Zacks) +17.52%
Dec-18-23 05:34AM	3 Russell 2000 Stocks That Are About to Get Absolutely Crushed (InvestorPlace)
Nov-14-23 07:00AM	908 Devices Announces MX908 Integration Capabilities (Business Wire) +19.12%
03:37PM	Loading…
Nov-09-23 03:37PM	908 Devices Inc. (NASDAQ:MASS) Q3 2023 Earnings Call Transcript (Insider Monkey) -11.83%
Nov-07-23 08:14AM	908 Devices Inc (MASS) Reports 9% Decrease in Q3 2023 Revenue, Narrows Full-Year Outlook (GuruFocus.com)
07:00AM	908 Devices Reports Third Quarter 2023 Financial Results and Narrows 2023 Revenue Outlook (Business Wire)
Nov-06-23 04:30PM	908 Devices and Terumo Blood and Cell Technologies Collaborate to Add On-line Analytics to Quantum Flex Cell Expansion System (Business Wire) -10.18%
Oct-31-23 07:00AM	908 Devices to Participate in Upcoming Investor Conferences (Business Wire) +12.95%
Oct-24-23 04:30PM	908 Devices Awarded $10.4M Order from the United States Air Force for its Handheld MX908 Device (Business Wire)
07:00AM	908 Devices to Report Third Quarter Financial Results on November 7, 2023 (Business Wire)
Sep-26-23 07:00AM	908 Devices Enters Initial Production Phase of US Department of Defense Aerosol and Vapor Chemical Agent Detector Program (Business Wire)
Sep-18-23 07:00AM	908 Devices Launches MAVERICK for Real-Time In-Line Monitoring of Multiple Bioprocess Parameters (Business Wire)
Sep-15-23 07:00AM	908 Devices to Participate in the Gilmartin Group Emerging Growth Company Showcase (Business Wire)
Aug-26-23 07:50AM	3 Cathie Wood Stocks With Parabolic Growth Potential, According to Wall Street (Motley Fool)
Aug-08-23 09:15AM	908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +22.01%
07:00AM	908 Devices Reports Second Quarter 2023 Financial Results and Updates 2023 Revenue Outlook (Business Wire)
Aug-07-23 07:00AM	908 Devices Partners with Tennessee State and Local Agencies in the Fight Against Drug Trafficking Through a New Pilot Program (Business Wire)
Jul-31-23 07:00AM	908 Devices Launches Remote and Continuous Area Monitoring for Aerosol and Vapor Detection (Business Wire) +9.26%
07:00AM	Loading…
Jul-25-23 07:00AM	908 Devices to Report Second Quarter Financial Results on August 8, 2023 (Business Wire)
Jul-16-23 08:42AM	Investors in 908 Devices (NASDAQ:MASS) have unfortunately lost 59% over the last year (Simply Wall St.)
Jul-13-23 05:42AM	908 Devices Inc. (MASS) Soars 8.5%: Is Further Upside Left in the Stock? (Zacks)
May-30-23 07:00AM	908 Devices Features its High-Speed, High-Resolution Separations Technology at the 71st ASMS Conference (Business Wire)
May-23-23 09:54AM	Too Cheap to Ignore: Cathie Wood Snaps Up These 2 Stocks Under $10 (TipRanks) +16.65%
07:00AM	908 Devices to Participate in the William Blair 43rd Annual Growth Stock Conference (Business Wire)
May-09-23 08:25AM	908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.16%
07:00AM	908 Devices Reports First Quarter 2023 Financial Results and Reiterates 2023 Revenue Outlook (Business Wire)
May-04-23 07:00AM	908 Devices Launches Data Analysis Visualization Tool for REBEL At-line Cell Culture Media Analyzer (Business Wire) +7.33%
Apr-26-23 07:00AM	Resilience Demonstrates Lower Cost of Perfusion Bioreactor Process Using 908 Devices REBEL At-line Analyzer (Business Wire)
Apr-25-23 07:00AM	908 Devices to Report First Quarter Financial Results on May 9, 2023 (Business Wire) -6.46%
Apr-18-23 11:14AM	Pinning Down 908 Devices Inc.'s (NASDAQ:MASS) P/S Is Difficult Right Now (Simply Wall St.)
Mar-08-23 02:22AM	Q4 2022 908 Devices Inc. Earnings Call (Thomson Reuters StreetEvents)
Mar-07-23 08:25AM	908 Devices Inc. (MASS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	908 Devices Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Revenue Outlook (Business Wire)
Feb-27-23 06:05PM	ViewRay (VRAY) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -5.01%
Feb-21-23 07:00AM	908 Devices to Participate in the Cowen 43rd Annual Healthcare Conference (Business Wire) -11.37%
Feb-14-23 07:00AM	908 Devices to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023 (Business Wire)
Feb-07-23 01:37PM	908 Devices Is Well Positioned, Analyst Says While Initiating Coverage (Benzinga)
Feb-06-23 05:16AM	Strong week for 908 Devices (NASDAQ:MASS) shareholders doesn't alleviate pain of one-year loss (Simply Wall St.)
Jan-17-23 07:00AM	908 Devices Unveils New Glucose and Lactate On-Line Device for Bioprocess Monitoring and Control (Business Wire) +8.95%
Dec-29-22 06:02AM	908 Devices Inc. (NASDAQ:MASS) Q3 2022 Earnings Call Transcript (Insider Monkey) +6.57%
Dec-07-22 07:00AM	MX908 Device Enables Correctional Facility Personnel to Quickly Identify Illegal Drugs in Incoming Mail (Business Wire)
Nov-16-22 06:24AM	908 Devices Third Quarter 2022 Earnings: EPS Beats Expectations (Simply Wall St.)
Nov-14-22 11:44AM	Why 908 Devices Stock Is Sinking Today (Motley Fool) -22.05%
10:05AM	908 Devices Inc. (MASS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	908 Devices Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Outlook (Business Wire)
Nov-10-22 07:00AM	908 Devices Records Strong Momentum in Life Sciences Sector (Business Wire) +25.29%
Nov-09-22 07:00AM	908 Devices Launches Pesticide Identification Capability to Thwart Illegal Marijuana Growing Operations (Business Wire) -9.45%
Nov-02-22 07:00AM	908 Devices to Participate in Upcoming Investor Conferences (Business Wire) -6.69%
Oct-19-22 07:00AM	908 Devices to Report Third Quarter 2022 Financial Results on November 14, 2022 (Business Wire)
Oct-12-22 05:00PM	908 Devices and CPI Improve mAbs Cell Culture Outcomes Using At-line Media Analysis (Business Wire)
Sep-29-22 07:50AM	Alphatec (ATEC) Soars 7%: Is Further Upside Left in the Stock? (Zacks)
Aug-09-22 04:00PM	908 Devices Inc. (MASS) Q2 2022 Earnings Call Transcript (Motley Fool) -12.42%
08:45AM	908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	908 Devices Reports Second Quarter 2022 Financial Results and Reiterates 2022 Revenue Outlook (Business Wire)
07:00AM	908 Devices Acquires TRACE Analytics, Enabling On-line Bioanalytics (Business Wire)
Jul-27-22 07:00AM	908 Devices to Participate in the Canaccord Genuity 42nd Annual Growth Conference (Business Wire) +6.48%
Jul-25-22 07:21AM	Even after rising 19% this past week, 908 Devices (NASDAQ:MASS) shareholders are still down 35% over the past year (Simply Wall St.)
Jul-19-22 07:00AM	908 Devices to Report Second Quarter 2022 Financial Results on August 9, 2022 (Business Wire) +11.23%
Jun-13-22 04:22PM	We Will Shine: Cathie Woods Optimism and Her 10 Most Ambitious Stock Picks (Insider Monkey)
Jun-02-22 07:00AM	908 Devices Showcases Technology for Accelerating Mass Spec Workflows in Presentations at ASMS (Business Wire)
May-26-22 07:00AM	908 Devices to Participate in the William Blair 42nd Annual Growth Stock Conference (Business Wire) +5.64%
May-11-22 02:30AM	908 Devices Inc. (MASS) Q1 2022 Earnings Call Transcript (Motley Fool) -23.59%
May-10-22 08:15AM	908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +14.40%
07:00AM	908 Devices Reports First Quarter 2022 Financial Results and Reiterates 2022 Revenue Outlook (Business Wire)
May-09-22 07:00AM	908 Devices Advances MX908 Handheld Device Capabilities (Business Wire) -9.99%
May-03-22 07:00AM	908 Devices Partners with Key Biomanufacturing Innovation Center (Business Wire)
Apr-21-22 07:00AM	908 Devices and CPI Team on Cell Culture Media Optimization for Improved Process Control in Bioprocessing Applications (Business Wire)
Apr-12-22 05:37PM	10 Best Stocks to Buy Now According to Billionaire Nicholas Pritzkers Tao Capital (Insider Monkey)
07:00AM	908 Devices to Report First Quarter Financial Results on May 10, 2022 (Business Wire)
Mar-08-22 05:58PM	Why 908 Devices Stock Rocketed 15% Higher Today (Motley Fool) +15.06%
Mar-07-22 10:30PM	908 Devices Inc. (MASS) Q4 2021 Earnings Call Transcript (Motley Fool)
05:15PM	908 Devices Inc. (MASS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	908 Devices Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Revenue Outlook (Business Wire)
Mar-02-22 04:30PM	908 Devices Appoints Tony J. Hunt, President and CEO, Repligen, to its Board of Directors (Business Wire)
Feb-15-22 07:00AM	908 Devices to Report Fourth Quarter and Full Year 2021 Financial Results on March 7, 2022 (Business Wire) +5.19%
Feb-14-22 12:24PM	908 Devices (NASDAQ:MASS) shareholders have endured a 80% loss from investing in the stock a year ago (Simply Wall St.)
Feb-08-22 07:00AM	908 Devices to Participate in Upcoming Investor Conferences (Business Wire)
Jan-21-22 11:37AM	15 Worst Stock Picks of Cathie Wood (Insider Monkey)
Jan-09-22 07:00PM	908 Devices Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021 (Business Wire)
Jan-07-22 07:00AM	908 Devices Announces GSK Purchases Fifth REBEL Cell Culture Media Analyzer (Business Wire)
Jan-04-22 05:00PM	908 Devices and U.S. Forest Service Announce Development Collaboration (Business Wire) -5.48%
Dec-23-21 01:38PM	MainStay VP Small Cap Growth Portfolio Buys Option Care Health Inc, Leslies Inc, Kratos Defense ... (GuruFocus.com)
Dec-22-21 09:16AM	Top 10 Stock Picks of Billionaire Nicholas Pritzker (Insider Monkey)
07:00AM	908 Devices Teams With World-Renowned Guardian Centers of Georgia for First Responder Training (Business Wire)
Nov-11-21 07:00AM	908 Devices to Participate in Upcoming Investor Conferences (Business Wire)
Nov-10-21 07:40PM	908 Devices Announces Pricing of Public Offering (Business Wire)
Nov-08-21 04:15PM	908 Devices Announces Launch of Public Offering (Business Wire)
Nov-04-21 11:03PM	908 Devices Inc. (MASS) Q3 2021 Earnings Call Transcript (Motley Fool) +11.03%

908 Devices, Inc. engages in the development of measurement devices for chemical and biochemical analysis. It offers products using mass spectrometry technology, an analytical technique for measuring the mass of charged molecules that is used in chemical analysis laboratories for applications, such as safety and security, food science, biotechnology, clinical diagnostics, and controlling industrial processes. Its products include desktops and handhelds. The company was founded by Kevin J. Knopp, Miller Scott, Steve Araiza, Andrew Bartfay, Michael Jobin, Christopher D. Brown, and Christopher J. Petty in 2012 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Knopp Kevin J.	President and CEO	Apr 16 '24	Option Exercise	1.75	47,000	82,250	458,981	Apr 16 04:11 PM
Brown Christopher D.	Chief Product Officer	Apr 01 '24	Option Exercise	1.75	3,600	6,300	884,994	Apr 02 04:06 PM
Griffith Joseph H. IV	Chief Financial Officer	Mar 26 '24	Option Exercise	1.58	8,437	13,330	93,437	Mar 27 04:16 PM
Griffith Joseph H. IV	Chief Financial Officer	Feb 02 '24	Sale	7.09	9,711	68,873	80,000	Feb 02 07:10 PM
Knopp Kevin J.	President and CEO	Feb 01 '24	Sale	7.00	9,071	63,461	411,981	Feb 02 04:39 PM
Griffith Joseph H. IV	Chief Financial Officer	Feb 01 '24	Sale	7.00	5,698	39,892	89,711	Feb 02 07:10 PM
Turner Michael S.	Chief Legal & Admin Officer	Feb 01 '24	Sale	6.99	5,232	36,559	9,105	Feb 02 04:40 PM
Brown Christopher D.	Chief Product Officer	Feb 01 '24	Sale	7.01	3,957	27,730	886,394	Feb 02 04:37 PM
Griffith Joseph H. IV	Chief Financial Officer	Dec 28 '23	Sale	12.08	6,000	72,480	80,000	Jan 02 05:01 PM
Brown Christopher D.	Chief Product Officer	Dec 21 '23	Sale	9.12	7,370	67,214	877,905	Dec 21 04:46 PM
Brown Christopher D.	Chief Product Officer	Dec 20 '23	Sale	9.10	5,235	47,638	885,275	Dec 21 04:46 PM
Brown Christopher D.	Chief Product Officer	Dec 19 '23	Sale	9.08	7,395	67,147	890,510	Dec 21 04:46 PM
Griffith Joseph H. IV	Chief Financial Officer	Dec 19 '23	Sale	9.08	5,580	50,666	86,000	Dec 21 04:47 PM
Brown Christopher D.	Chief Product Officer	Jun 07 '23	Sale	10.03	4,470	44,834	897,905	Jun 09 04:17 PM
Knopp Kevin J.	President and CEO	Jun 05 '23	Option Exercise	1.75	28,500	49,875	396,348	Jun 05 04:07 PM
Knopp Kevin J.	President and CEO	May 23 '23	Sale	10.12	60,000	607,200	367,848	May 25 04:08 PM
Brown Christopher D.	Chief Technology Officer	May 23 '23	Sale	10.02	10,000	100,200	892,375	May 25 04:12 PM

Open in Screener

SYRS

Syros Pharmaceuticals Inc.

Apr 24 • 04:00PM ET

5.07

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

SYRS Syros Pharmaceuticals Inc. daily Stock Chart

Held by: VTI VXF IWC AVSC

Index	-	P/E	-	EPS (ttm)	-5.77	Insider Own	30.36%	Shs Outstand	26.45M	Perf Week	-0.78%
Market Cap	134.10M	Forward P/E	-	EPS next Y	-3.32	Insider Trans	12.34%	Shs Float	18.42M	Perf Month	-20.78%
Income	-164.57M	PEG	-	EPS next Q	-0.85	Inst Own	44.72%	Short Float	10.10%	Perf Quarter	-23.53%
Sales	9.94M	P/S	13.49	EPS this Y	38.30%	Inst Trans	88.10%	Short Ratio	8.79	Perf Half Y	129.41%
Book/sh	0.63	P/B	8.05	EPS next Y	7.49%	ROA	-79.76%	Short Interest	1.86M	Perf Year	79.79%
Cash/sh	5.28	P/C	0.96	EPS next 5Y	-	ROE	-227.94%	52W Range	2.09 - 8.17	Perf YTD	-34.92%
Dividend Est.	-	P/FCF	-	EPS past 5Y	21.16%	ROI	-235.96%	52W High	-37.94%	Beta	1.77
Dividend TTM	-	Quick Ratio	3.95	Sales past 5Y	128.79%	Gross Margin	77.33%	52W Low	142.56%	ATR (14)	0.45
Dividend Ex-Date	-	Current Ratio	3.95	EPS Y/Y TTM	54.86%	Oper. Margin	-1273.27%	RSI (14)	44.36	Volatility	7.07% 9.56%
Employees	68	Debt/Eq	3.73	Sales Y/Y TTM	-33.23%	Profit Margin	-1656.51%	Recom	1.00	Target Price	19.25
Option/Short	Yes / Yes	LT Debt/Eq	3.19	EPS Q/Q	-1167.09%	Payout	-	Rel Volume	0.00	Prev Close	5.07
Sales Surprise	-80.65%	EPS Surprise	-90.56%	Sales Q/Q	151.19%	Earnings	Mar 27 BMO	Avg Volume	211.73K	Price	5.07
SMA20	-1.22%	SMA50	-17.64%	SMA200	6.76%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-04-20	Upgrade	H.C. Wainwright	Neutral → Buy	$11 → $15
Sep-22-20	Initiated	Alliance Global Partners	Buy	$18
Jan-17-20	Downgrade	Wedbush	Outperform → Neutral
Mar-08-19	Resumed	JMP Securities	Mkt Outperform	$18
Feb-14-19	Resumed	Oppenheimer	Outperform	$13
Nov-05-18	Upgrade	ROTH Capital	Neutral → Buy
Mar-13-18	Reiterated	Wedbush	Outperform	$11 → $13
Oct-31-17	Resumed	Piper Jaffray	Overweight	$30
Oct-23-17	Initiated	ROTH Capital	Neutral	$15
Aug-10-17	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform

Apr-10-24 09:49AM	Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML (Zacks)
08:30AM	Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock? (Zacks)
Apr-09-24 07:00AM	Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression (Business Wire) +22.22%
Apr-02-24 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.04%
Mar-28-24 10:06AM	Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call Transcript (Insider Monkey) -8.39%
11:53AM	Loading…
Mar-27-24 11:53AM	SYRS Stock Earnings: Syros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -6.56%
07:30AM	Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update (Business Wire)
Mar-25-24 07:00AM	Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial (Business Wire)
Mar-20-24 07:00AM	Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024 (Business Wire)
Feb-27-24 07:00AM	Syros to Participate in TD Cowen 44th Annual Health Care Conference (Business Wire)
Jan-31-24 04:00PM	3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential (InvestorPlace)
Jan-19-24 10:43AM	Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why (Zacks)
Jan-18-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Syros Pharmaceuticals, Inc. (SYRS) is a Great Choice (Zacks) -6.09%
Jan-17-24 08:50AM	Syros Pharmaceuticals, Inc. (SYRS) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jan-16-24 12:00PM	What Makes Syros Pharmaceuticals, Inc. (SYRS) a New Buy Stock (Zacks)
09:55AM	Loading…
09:55AM	Wall Street Analysts Predict a 199.31% Upside in Syros Pharmaceuticals, Inc. (SYRS): Here's What You Should Know (Zacks)
Jan-11-24 08:48AM	Why Syros Pharmaceuticals (SYRS) Stock Might be a Great Pick (Zacks)
Jan-08-24 07:00AM	Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene (Business Wire)
Jan-03-24 11:03PM	Steven Cohen's Point72 Asset Management Acquires New Stake in Syros Pharmaceuticals (GuruFocus.com) -9.95%
Dec-19-23 07:27AM	Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants (Business Wire) +30.93%
Dec-07-23 09:44AM	Syros (SYRS) Rises on Upbeat Initial Study Data on Tamibarotene (Zacks) +15.92%
Dec-06-23 07:00AM	Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine (Business Wire) +42.55%
Dec-03-23 04:17PM	Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential (InvestorPlace)
Nov-21-23 07:30AM	Syros to Participate in Upcoming Investor Conferences (Business Wire)
Nov-15-23 01:08PM	Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2023 Earnings Call Transcript (Insider Monkey) +11.76%
Nov-14-23 07:30AM	Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update (Business Wire)
Nov-07-23 07:30AM	Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023 (Business Wire) +5.36%
Oct-02-23 08:45AM	Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company (Business Wire) -18.73%
Sep-07-23 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-08-23 09:49PM	Q2 2023 Syros Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
09:05AM	Loading…
09:05AM	Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update (Business Wire)
Aug-04-23 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.93%
Aug-01-23 07:30AM	Syros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023 (Business Wire)
Jul-27-23 06:29AM	The Petri Dish: Pfizer ends Syros collab; Editas hires 37-year Biogen vet (American City Business Journals)
Jul-21-23 05:40PM	Pfizer to end license deal with Syros for blood disorder therapies (Reuters)
Jul-05-23 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-22-23 08:14PM	Strength Seen in IGM Biosciences, Inc. (IGMS): Can Its 7.6% Jump Turn into More Strength? (Zacks)
Jun-13-23 08:00AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
Jun-08-23 07:30AM	Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference (Business Wire)
Jun-01-23 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-25-23 05:05PM	Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting (Business Wire) -5.06%
08:44AM	One Syros Pharmaceuticals Insider Raised Stake By 212% In Previous Year \ (Simply Wall St.)
May-13-23 10:15AM	Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-10-23 10:08PM	Q1 2023 Syros Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +10.29%
08:45AM	Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update (Business Wire)
May-09-23 07:00AM	Syros to Present at JMP Securities 2023 Life Sciences Conference (Business Wire)
May-07-23 08:40PM	ImmunityBio (IBRX) Stock Jumps 43.2%: Will It Continue to Soar? (Zacks)
May-03-23 07:30AM	Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023 (Business Wire)
May-02-23 07:00AM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.95%
Mar-06-23 09:48AM	Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-04-23 07:08AM	Syros Pharmaceuticals Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Mar-02-23 10:02PM	Q4 2022 Syros Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
09:35AM	Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update (Business Wire)
Feb-28-23 07:30AM	Syros to Participate in Upcoming Investor Conferences in March (Business Wire)
Feb-23-23 07:30AM	Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023 (Business Wire)
Feb-09-23 04:05PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.61%
Feb-01-23 09:43AM	Strength Seen in Syros Pharmaceuticals, Inc. (SYRS): Can Its 5.4% Jump Turn into More Strength? (Zacks)
Jan-26-23 07:00AM	Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome (Business Wire)
Jan-09-23 07:00AM	Syros Announces Clinical Updates and 2023 Strategic Priorities (Business Wire)
Dec-23-22 04:05PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-16-22 06:47AM	One Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) insider upped their stake by 212% in the previous year (Simply Wall St.) -7.73%
Dec-12-22 07:30AM	Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS (Business Wire) +5.04%
Dec-10-22 10:00AM	Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial (Business Wire)
Dec-05-22 07:00AM	Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10 (Business Wire)
Nov-22-22 07:30AM	Syros to Participate at Piper Sandler 34th Annual Healthcare Conference (Business Wire)
Nov-14-22 08:45AM	Syros Pharmaceuticals, Inc. (SYRS) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -8.04%
07:30AM	Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update (Business Wire)
Nov-07-22 07:30AM	Syros to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022 (Business Wire)
Nov-04-22 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-03-22 09:01AM	Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting (Business Wire)
Oct-05-22 04:01PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-23-22 12:00PM	Syros Pharmaceuticals, Inc. (SYRS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) -10.88%
Sep-16-22 04:05PM	Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement (Business Wire)
Sep-15-22 04:13PM	Syros and Tyme Technologies Announce Stockholder Approval of Merger (GlobeNewswire)
Sep-14-22 01:26PM	Syros (SYRS) Up on FDA's Orphan Tag for Pancreatic Cancer Drug (Zacks) -7.56%
Sep-13-22 04:01PM	Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer (Business Wire)
Sep-07-22 07:30AM	Syros to Present at H.C. Wainwright 24th Annual Global Investment Conference (Business Wire)
Sep-02-22 04:01PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-09-22 08:45AM	Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:30AM	Edited Transcript of SYRS.OQ earnings conference call or presentation 9-Aug-22 12:30pm GMT (Thomson Reuters StreetEvents)
07:30AM	Syros Reports Second Quarter 2022 Financial Results and Provides a Corporate Update (Business Wire)
Aug-04-22 04:01PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-03-22 04:01PM	Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS (Business Wire) +7.63%
Aug-02-22 07:30AM	Syros to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022 (Business Wire)
Jul-28-22 10:33AM	Mass. M&A activity picks up among life sciences firms (American City Business Journals) -5.67%
Jul-13-22 12:00PM	Syros Pharmaceuticals, Inc. (SYRS) Moves to Strong Buy: Rationale Behind the Upgrade (Zacks)
Jul-06-22 11:31AM	Biotech Stock Roundup: VRTX's Regulatory Update, TYME Gains on Acquisition & More (Zacks) -8.03%
Jul-05-22 04:48PM	Syros to acquire New Jersey biotech Tyme Technologies (American City Business Journals)
07:59AM	TYME Technologies Shares Surge On Merger Agreement With Syros Pharma (Benzinga)
07:00AM	Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement (Business Wire)
Jul-01-22 04:01PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.47%
Jun-20-22 07:43AM	CRISPR Therapeutics AG (CRSP) Moves 8.3% Higher: Will This Strength Last? (Zacks)
Jun-08-22 07:30AM	Syros to Present at JMP Securities Life Sciences Conference (Business Wire)
Jun-03-22 04:01PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +15.30%
May-16-22 08:45AM	Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -14.38%
07:30AM	Syros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides a Corporate Update (Business Wire)
May-13-22 08:13AM	Strength Seen in Immatics (IMTX): Can Its 5.3% Jump Turn into More Strength? (Zacks) +6.86%

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Roth David	Chief Medical Officer	Apr 03 '24	Sale	4.95	10,451	51,732	0	Apr 05 04:30 PM
Roth David	Chief Medical Officer	Apr 02 '24	Sale	4.98	150	747	10,451	Apr 02 04:58 PM
AKKARAJU SRINIVAS	Director	Dec 21 '23	Buy	4.42	904,977	3,999,998	1,786,427	Dec 26 05:24 PM
Roth David	Chief Medical Officer	Dec 12 '23	Sale	4.95	6,287	31,121	0	Dec 14 04:24 PM
Roth David	Chief Medical Officer	Dec 06 '23	Sale	3.95	6,287	24,834	6,287	Dec 08 04:23 PM
Roth David	Chief Medical Officer	Jul 31 '23	Sale	3.95	7,348	29,025	0	Aug 02 04:21 PM
Olson Eric R	Chief Scientific Officer	Jul 17 '23	Sale	3.50	689	2,412	6,661	Jul 18 08:27 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

MASS

908 Devices Inc

SYRS

Syros Pharmaceuticals Inc.

Upgrade your FINVIZ experience